Dr. Kothandaraman Narasimhan

Home >> Research Staff >> Kothandaraman Narasimhan, PhD
Dr. Kothandaraman Narasimhan

Head of Proteomics & Metabolomics Service Unit
Head of Agilent Microarray Service Unit
Ovarian Cancer Research Group
Colon Cancer Research Group

Dr. Narasimhan research interests are in two fields associated with Clinical Medicine. These include cancer biology and genetics of inherited chronic disease conditions. In the field of cancer biology I'm specifically interested in solid epithelial tumor biology. I have done 10 years research in the field of gynecological malignancies especially ovarian cancer and prenatal diagnosis. My research has resulted in publication of more than 20 scientific research articles with high impact factor in reputedinternational journals and two book chapters. My research has identified key role of cell cycle transcription factors and their association with the progression of the diseases. My studies have led to the identification of novel biomarkers for ovarian cancer which could be used as both diagnostic and prognostic markers.

At the CEGMR, my current research focus at CEGMR is to establish thrust research areas insolid epithelial malignancies including ovarian, breast and colorectal cancer, MiRNA (miRNOME) as potential biomarkers in body fluids for early detection of epithelial malignancies, cancer metabolomics or Lipidomics, and carrier screening approaches for chronic disorders using Next Generation Sequencing techniques.

Funded Projects:
Identification of circulating nucleic acids as markers for colorectal cancer (Funded by CEGMR).

Selected Publications:
  1. Manikandan J, Narasimhan K, Prakash HM, Pushparaj P. Deciphering the structure and function of Fc epsilon RI/Mast cell axis in the regulation of allergy and anaphylaxis: A functional genomics paradigm. Cellular and Molecular Life Sciences 2011. Impact Factor:  7.047 (In Press)

  2. Stephen C L Koh , Razvi K, Chan YH, Narasimhan K, Ilancheran A, Low JL, Choolani M. The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Archives of Gynecology and Obstetrics. 284 (1) 183-90, 2011.

  3. Mandeep K, Macpherson CR, Schmeier S, Narasimhan K, Choolani M and Bajic VB. In Silico discovery of transcription factors as potential diagnostic biomarkers of ovarian cancer. BMC Systems Biology 2011 (in Press) Impact Factor: 3.57
  4. Kanimozhi S, Basheer C , Narasimhan K, Lin L, Koh S , Feng Xue , Choolani M , Hian Kee Lee HK., Application of porous membrane protected micro-solid-phase-extraction combined with gas chromatography-mass spectrometry for the determination of estrogens in ovarian cyst fluid samples. Analytica Chimica Acta, 2011 Feb 14;687(1):56-60. Impact Factor: 3.757

  5. Koh SC, Razvi K, Chan YH, Narasimhan K, Ilancheran A, Low JJ, Choolani M; The Ovarian Cancer Research Consortium of SE Asia. The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Arch Gynecol Obstet. 2010. Aug 1. PMID: 20680316

  6. Das K, Lorena PD, Ng LK, Shen L, Lim D, Siow WY, Narasimhan K, Teh M, Choolani M, Putti TC, Salto-Tellez M. Pathology. 2010;42(6):540-6.. Aurora-A expression, hormone receptor status and clinical outcome in hormone-related cancers. PATHOLOGY  42(6):540-6. IF: 2.324

  7. Baig S, Ho SS, Ng BL, Chiu L, Koay ES, Leow GH, Gole L, Narasimhan K, Chan J, Sun X, Chan YH, Rauff M, Su LL, Biswas A, Choolani M. Development of quantitative-fluorescence polymerase chain reaction for the rapid prenatal diagnosis of common chromosomal aneuploidies in 1,000 samples in Singapore. SINGAPORE MED J. 2010;51(4):343-8. PMID: 20505915

  8. Narasimhan K, Bajic VB, Brendan PN, Huak CY, Keow PB, Razvi K, Salto-Tellez M, Choolani M. E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer. 2010 Feb 24;10:64.PMID: 20181230 IF: 3.08

Last Update
1/6/2016 9:48:27 AM